• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

johnsonandjohnson

J&J approaches Actelion

November 28, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through. J&J’s CEO Alex Gorsky said this year that the company is interested in deals […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Roche, Sanofi-Aventis

Clearside Biomedical names McElheny as biz dev veep | Personnel Moves, Nov. 8, 2016

November 8, 2016 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development. The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Personnel Tagged With: Clearside Biomedical, johnsonandjohnson

Antibacterial coated suture wins WHO recommendation

November 4, 2016 By Sarah Faulkner

Ethicon

Ethicon said today that its triclosan-coated suture was included in the new “Global Guidelines for the Prevention of Surgical Site Infections (SSI)” by the World Health Organization. The guidelines are the 1st global guidelines for preventing surgical site infections. “The panel suggests the use of triclosan-coated sutures for the purpose of reducing the risk of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Surgical Tagged With: Ethicon, johnsonandjohnson, World Health Organization

J&J’s Acclarent to pay $18m over off-label marketing charges

July 22, 2016 By Fink Densford

Johnson & Johnson (NYSE:JNJ) subsidiary Acclarent will pay $18 million to resolve allegations over false claims submitted to Medicare and other federal health care programs in relation to marketing its Relieva Stratus MicroFlow sinus spacer as a drug-delivery device without FDA clearance. The company won FDA clearance in 2006 to market the Stratus as a […]

Filed Under: Drug-Device Combinations, Legal News Tagged With: Acclarent Inc., johnsonandjohnson

Ichor Medical inks $85m drug-device deal with J&J

April 13, 2015 By Brad Perriello

Ichor Medical inks drug-device deal with J&J

Filed Under: Drug-Device Combinations Tagged With: Hepatitis, Ichor Medical Systems, Janssen Pharmaceuticals, johnsonandjohnson

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 6
  • Page 7
  • Page 8

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS